biostudies-literatureUnknown36(10)Kubasch ASAmgenThe EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombopLeukemia2519-2527https://www.ebi.ac.uk/biostudies/studies/S-EPMC9522582biostudies-literatureProspective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.PMC9522582Thiede CHuetter-Kroenke MLSlama BAdes LGiagounidis AGotze KSFenaux PDe Renzis BCony-Makhoul PMetzeler KHMies ASapena RKubasch ASSchlenk RFJersemann KGloaguen SGourin MPMetzgeroth GPlatzbecker UDiaz JMTDimicoli-Salazar SSchipp DHerbst RLaribi KPark SSockel KJonasova ATiebel OChermat FfalseProspective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombop2022-01-01T00:00:00Z2022 Oct2026-05-31T15:57:12.162Z2024-12-04T01:58:26.498ZS-EPMC95225823607110010.1038/s41375-022-01669-z